Continuous erythropoiesis receptor activator (CERA): An erythropoiesis-stimulating agent for the treatment of anemia in patients with chronic kidney disease

Formulary

Volumn 42, Issue 4, 2007, Pages 233-244

  O'Mara, Neeta Bahal ^a   Kapoian, Toros ^b  

^a Dialysis Clinics Inc   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; CISPLATIN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; LEVODOPA; METFORMIN; METHOTREXATE; METHYLDOPA; MIRCEVA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHENYTOIN; PLACEBO; PROCAINAMIDE; PROTON PUMP INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SULFONAMIDE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANEMIA; BONE MARROW DISEASE; CARDIOVASCULAR DISEASE; CELLULITIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HEADACHE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; HYPERTENSION; HYPOTENSION; MUSCLE CRAMP; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS;

EID: 34248162009     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. National Kidney Foundation web site. Available at: http://www.kidney.org. Accessed March 15, 2007.
2. Daugirdas JT, Blake PG, Ing TS. Handbook of Dialysis. 4th ed. New York, NY: Lippincott Williams & Wilkins; 2006.
3. Kazmi WH, Kausz AT, Khan S, et al. Anemia: An early complication of chronic renal insufficiency. Am J Kid Dis. 2001;38:803-812.
4. Hsu C-Y, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13:504-510.
5. Kausz AT, Kliger A, Port FK, et al. Opportunities to optimize anemia management among chronic kidney disease patients - results from the STRIDE registry [abstract]. J Am Soc Nephrol. 2002;13:640A. Abstract SU-PO836.
6. Silverberg DS.Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141-146.
7. Painter P, Moore G, Carlson L, et al. Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. Am J Kidney Dis. 2002;39:257-265.
8. Valderrábano F, Jofre R, López-Gómez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis. 2001;38:443-464.
9. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:94-111.
10. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 suppl 3):S11-145.
11. Singh AK, Szczech L, Tang, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
12. Drueke TB, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084.
13. Epogen [package insert]. Thousand Oaks, Calif: Amgen; 2007.
14. Procrit [package insert]. Raritan, NJ: Ortho Biotech; 2007.
15. Aranesp [package insert]. Thousand Oaks, Calif: Amgen; 2007.
16. Macdougall IC. CERA (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436-440.
17. Macdougall IC, Reigner B, Dougherty FC. Consistent pharmacokinetic properties of CERA (continuous erythropoietin receptor activator) in healthy volunteers and in patients with CKD. Poster presented at: National Kidney Foundation Spring 2006 Clinical Meeting; April 19-23, 2006; Chicago,Ill.
18. Jarsch M, Kubbies M, Lanzendörfer M, Haselbeck A, Brandt M. CERA acts differently at the erythropoietin (EPO) receptor compared with epoetin beta: UT-7 and CD34+ cell stimulation assays. Poster presented at: The American Society of Nephrology 39th Annual Meeting; November 14-19, 2006; San Diego, Calif.
19. Macdougall IC, Bailon P, Tare N, Pahlke W, Pill J, Brandt M. CERA (continuous erythropoiesis receptor activator) for the treatment of renal anemia: An innovative agent with unique receptor binding characteristics and prolonged serum half-life. Poster presented at: The American Society of Nephrology 36th Annual Meeting; November 12-17, 2003; San Diego, Calif.
20. Reigner B, Jordan P, Pannier A, Glaspy J. CERA (continuous erythropoiesis receptor activator), an innovative erythropoietic agent: Dose-dependent response in phase I studies. Poster presented at: American Society of Clinical Oncology 39th Annual Meeting; May 31-June 3, 2003; Chicago, Ill.
21. Dougherty FC, Reigner B, Jordan P, Pannier A. Continuous erythropoietin receptor activator (CERA) provides dose-dependent erythropoietic activity with a prolonged half-life in healthy volunteers. Poster presented at: 29th European Society for Medical Oncology Congress; October 29-November 2, 2004; Vienna, Austria.
22. Macdougall IC, Robson R, Opatrna S, et al. Pharmacologic profile of CERA (continuous erythropoietin receptor activator) in chronic kidney disease (CKD) patients following intravenous (IV) and subcutaneous (SC) administration. Poster presented at: The American Society of Nephrology 38th Annual Meeting; November 8-13,2005; Philadelphia, Pa.
23. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1211-1215.
24. Provenzano R, Besarab A, Macdougall IC, Dougherty FC, Beyer U; on behalf of the BA16528 study group. CERA (continuous erythropoietin receptor activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis. Poster presented at: The American Society of Nephrology 37th Annual Meeting; October 29-November 1,2004; St. Louis, Mo.
25. Besarab A, Provenzano R, Macdougall IC, et al. Dose-dependent erythropoietic responses to subcutaneous (SC) CERA (continuous erythropoietin receptor activator) in a multi-dose study of patients with chronic kidney disease not on dialysis. Poster presented at: The American Society of Nephrology 38th Annual Meeting; November 8-13, 2005; Philadelphia, Pa.
26. Provenzano R, Besarab A, Macdougall IC, et al. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels with administration intervals up to 3 weeks in chronic kidney disease patients not on dialysis. Poster presented at: The American Society of Nephrology 38th Annual Meeting; November 8-13, 2005; Philadelphia, Pa.
27. Besarab A, Beyer U, Dougherty FC; on behalf of the BA16285 extension study group. Long-term intravenous CERA (continuous erythropoietin receptor activator) maintains hemoglobin concentrations in hemodialysis patients. Poster presented at: The 3rd World Congress of Nephrology; June 26-30, 2005; Singapore.
28. Locatelli F, Villa G, Arias M, Marchesi D, Dougherty FC, Beyer U; on behalf of the BA16286 study group. CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks. Poster presented at: The American Society of Nephrology 37th Annual Meeting; October 29-November 1, 2004; St. Louis, Mo.
29. Dougherty FC, Reigner B, Beyer U. Dose-dependent erythropoietic responses to subcutaneous CERA (continuous erythropoiesis receptor activator) in a multiple-dose study of dialysis patients with chronic renal anemia. Poster presented at: 41st European Renal Association-European Dialysis and Transplant Association Congress; May 15-18, 2004; Lisbon, Portugal.
30. Locatelli F, Villa G, Beyer U, Dougherty FC; on behalf of the BA16286 extension study group. Subcutaneous CERA (continuous erythropoietin receptor activator) maintains hemoglobin concentrations with dosing intervals, up to 4 weeks in dialysis patients. Poster presented at: 42nd European Renal Association-European Dialysis and Transplant Association Congress; June 4-7,2005; Istanbul, Turkey.
31. Macdougall IC, Walker R, Provenzano R, et al; on behalf of the ARCTOS Study Investigators. CERA (continuous erythropoietin receptor activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis. Poster presented at: The American Society of Nephrology 39th Annual Meeting; November 14-19, 2006; San Diego, Calif.
32. Canaud B, Braun J, Locatelli F, et al; on behalf of the STRIATA Study Investigators. Intravenous (IV) CERA (continuous erythropoietin receptor activator) administered once every 2 weeks maintains stable haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Poster presented at: 43rd European Renal Association-European Dialysis and Transplant Association Congress; July 15-18, 2006; Glasgow, Scotland.
33. Sulowicz W, Locatelli F, Balla J, et al; on behalf of the PROTOS Study Investigators. Subcutaneous (SC) CERA (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Poster presented at: 43rd European Renal Association-European Dialysis and Transplant Association Congress; July 15-18, 2006; Glasgow, Scotland.
34. Klinger M, Arias M, Vargemezis V, et al; on behalf of the AMICUS Study Investigators. CERA (continuous erythropoietin receptor activator) administered at extended intervals corrects Hb levels in patients with CKD on dialysis. Poster presented at: The American Society of Nephrology 39th Annual Meeting; November 14-19, 2006; San Diego, Calif.
35. Fishbane S, Levin NW, Mann JFE, et al; on behalf of the MAXIMA Study Investigators. IV CERA (continuous erythropoietin receptor activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1-3 times per week in patients with CKD on dialysis. Poster presented at: The American Society of Nephrology 39th Annual Meeting; November 14-19, 2006; San Diego, Calif.
36. Levin NW, Imbasciati E, Combe C, et al; on behalf of the MAXIMA Study Investigators. Adequate Hb levels are maintained with IV CERA (continuous erythropoietin receptor activator) administered up to once monthly in dialysis patients irrespective of age, gender, or diabetic status. Poster presented at: The American Society of Nephrology 39th Annual Meeting; November 14-19, 2006; San Diego, Calif.
37. Locatelli F, Sulowicz W, Harris K, et al; on behalf of the PROTOS Study Investigators. SC CERA (continuous erythropoietin receptor activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from SC epoetin 1-3 times per week in patients with CKD on dialysis. Poster presented at: The American Society of Nephrology 39th Annual Meeting; November 14-19, 2006; San Diego, Calif.
38. Ryckelynck J-P, Harris K, Selgas R, et al; on behalf of the PROTOS Study Investigators. SC CERA (continuous erythropoietin receptor activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status. Poster presented at: The American Society of Nephrology 39th Annual Meeting; November 14-19, 2006; San Diego, Calif.
39. Dougherty FC, Beyer U. The safety and tolerability profile of continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease on dialysis is characteristic of this patient population. Poster presented at: The 3rd World Congress of Nephrology; June 26-30, 2005; Singapore.
40. Dougherty FC, Beyer U. No changes in blood pressure in dialysis patients after 12 months of treatment with IV or SC CERA (continuous erythropoietin receptor activator). Poster presented at: The 3rd World Congress of Nephrology; June 26-30, 2005; Singapore.
41. Locatelli F, Aljama P, Barany P, et al. Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: Where are we now and where do we go from here? Nephrol Dial Transplant. 2004;19:288-293.